Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selinexor in Relapsed Small Cell Lung Cancer
NCT02351505Phase 2Terminated
- Start
- May 2015
- Primary completion
- Dec 2015
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of selinexor in small cell lung cancer (SCLC). Primary endpoint: Progression Free Survival at 4 years. Started May 2015; status: terminated.
02
Drugs
selinexor
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT02351505.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02351505.